CN104383033A - Compound ginkgo leaf preparation for treating myocardial ischemia and hypoxia injury and preparation method of compound ginkgo leaf preparation - Google Patents
Compound ginkgo leaf preparation for treating myocardial ischemia and hypoxia injury and preparation method of compound ginkgo leaf preparation Download PDFInfo
- Publication number
- CN104383033A CN104383033A CN201410592632.1A CN201410592632A CN104383033A CN 104383033 A CN104383033 A CN 104383033A CN 201410592632 A CN201410592632 A CN 201410592632A CN 104383033 A CN104383033 A CN 104383033A
- Authority
- CN
- China
- Prior art keywords
- preparation
- chinese medicine
- extract
- folium
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 235000011201 Ginkgo Nutrition 0.000 title claims abstract description 22
- 235000008100 Ginkgo biloba Nutrition 0.000 title claims abstract description 22
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 16
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 16
- 241000218628 Ginkgo Species 0.000 title claims description 20
- 230000006378 damage Effects 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 title abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 title abstract 2
- 230000007954 hypoxia Effects 0.000 title abstract 2
- 208000014674 injury Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 239000000284 extract Substances 0.000 claims description 35
- 241000208340 Araliaceae Species 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 239000001509 sodium citrate Substances 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- -1 dry Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract description 4
- 235000008440 Crataegus cuneata Nutrition 0.000 abstract 1
- 244000160089 Crataegus cuneata Species 0.000 abstract 1
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- 210000002216 heart Anatomy 0.000 description 14
- 229940079593 drug Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000001105 femoral artery Anatomy 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 4
- 229960001008 heparin sodium Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 102000003896 Myeloperoxidases Human genes 0.000 description 3
- 108090000235 Myeloperoxidases Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000009982 suxiao jiuxinwan Substances 0.000 description 1
- 230000004873 systolic arterial blood pressure Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000009561 tongxinluo Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 229940020839 verapamil injection Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of a traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating myocardial ischemia and hypoxia injury and a preparation method of the compound ginkgo leaf preparation. The traditional Chinese medicine composition comprises the following raw materials: Chinese hawthorn leaves, ginkgo leaves and ginseng leaves.
Description
Technical field:
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition and preparation method thereof for the treatment of myocardial ischemia-anoxemia damage.
Background technology:
Oxygen is the essential condition of tissue, organ and cells play normal function.Anoxia refers to that the oxygen needed for vital movement can not obtain sufficient supply, and then the phenomenon of damage body.Myocardial ischemia/anoxia causes myocardial damage, necrosis and ARR main cause, is the main mechanism that ischemic heart desease occurs.Current research is thought, the damage that myocardial ischemia-anoxemia causes is mainly due to Ca
2+the reasons such as the infiltration of the accumulation of the mesostates such as overload, lactic acid, the activation of myocardial cell membrane phospholipase, the formation of oxygen-derived free radicals and neutrophilic granulocyte cause.Meanwhile, ischemia/anoxia not only depends on intensity and the persistent period of stimulation to the damage that cardiac muscle causes, and individual or target organ also plays an important role to the tolerance stimulated, and therefore, if can improve body to hypoxic-ischemic tolerance, seems particularly necessary.
In prior art, the medicines such as Aspirin, nitrate, statin are helpful to myocardial ischemia/anoxia, but side effect is more, cross Wigner Ville distribution is had in Chinese medicine preparation, SUXIAO JIUXIN WAN, Radix Salviae Miltiorrhizae Tabellae, FUFANG DANSHEN PIAN, Heart pill of Musk, DIAOXINXUE KANG, the heart can relax, arteria coronaria peaceful, Tongxinluo, Nuodikang, gingko leaf preparation etc., the expensive Chinese crude drug of the many uses of these medicines, and long-term taking patient burden is heavy.
Folium Crataegi 1000g price 6.0 yuan
Folium Ginkgo 1000g price 5.0 yuan
Folium Ginseng 1000g price 60.0 yuan
On the basis of existing technology, use abundance, low-cost multiple Chinese herbal medicine is tested in the present invention, unexpected discovery, by Folium Crataegi, Folium Ginkgo, Folium Ginseng is prepared into Chinese medicine compound through extraction, greatly reduces drug dose and cost, finds that three has synergistic function simultaneously.
Summary of the invention
The object of the invention is that providing a kind of treats Chinese medicine composition of myocardial ischemia-anoxemia damage and preparation method thereof, and this curative effect of medication is definite, has no side effect.
The present invention treats myocardial ischemia-anoxemia Chinese medicine composition, is prepared from by the raw material of Chinese medicine medicine of following weight ratio
Folium Crataegi 20-50g
Folium Ginkgo 10-30g
Folium Ginseng 10-40g
Preferably
Folium Crataegi 40-50g
Folium Ginkgo 20-30g
Folium Ginseng 30-40g
Above dosage can be prepared into pharmaceutical preparation as 100, tablet, granule 100g, capsule 100 etc.
Treatment myocardial ischemia-anoxemia Chinese medicine composition of the present invention, can be prepared into the pharmaceutical dosage form that any one can be taken, and preferred oral dosage form is as tablet, granule, capsule, oral liquid etc.
The present invention further provides the preparation method for the treatment of myocardial ischemia-anoxemia Chinese medicine composition of the present invention: described method is processed through extraction or other modes by raw material of Chinese medicine, make pharmaceutically active substance, subsequently, with this material for raw material, add medicine acceptable carrier when needing, make pharmaceutical preparation according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can be obtained by the common raw material of Chinese medicine that extracts, also can obtain by other means, as: by pulverizing, squeezing, calcine, grind, sieve, percolation, extraction, water extraction, alcohol extraction, ester carry, the material that method obtains, these active substances can be extractum form such as ketone is carried, chromatography, can be dry extract also can be fluid extract, need to determine to make different concentration according to the difference of preparation.
Preferably, preparation method of the present invention is as follows:
Respectively by above medical material coarse crushing, get Folium Crataegi and Folium Ginkgo, add 6-10 times of water gaging reflux, extract, 2 times, each 1 hour, merging filtrate, being evaporated to relative density is 1.05, adds ethanol, 50-65% concentration precipitate with ethanol, ethanol reclaim under reduced pressure, obtain extractum, vacuum drying, obtains Folium Crataegi, Folium Ginkgo extract.
Get Folium Ginseng, add 6-10 times amount 50-70% reflux, extract, 2 times, each 1 hour, merging filtrate, decompression recycling ethanol, obtains extractum, and suitable quantity of water is dissolved, defat with petroleum ether, and water liquid part is dry, obtains extract of Radix Ginseng leaf.
The mixture of above extract is exactly pharmaceutically active substance of the present invention, with this pharmaceutically active substance for active component, and the mixing of medicine acceptable carrier, according to galenic pharmacy routine techniques, pharmaceutical preparations composition of the present invention can be obtained.
As: take above extract, add appropriate amount of starch, wetting agent moistening, granulate, dry, incapsulate and can obtain capsule, tabletting can obtain tablet.
The present invention is preferably prepared into effervescent granule, and its preparation method is as follows:
Take above extract 100 parts, add citric acid 0-2 part, malic acid 2-0 part, sodium bicarbonate 2 parts, lactose 30-40 part, sodium lauryl sulphate 2-5 part, sodium citrate 25-35 part, with ethanol wet, granulate, dry, granulate, to obtain final product.
The present invention, before determining prescription, has carried out the side of tearing open and prescription drug efficacy study to raw medicinal material and mutual proportion compatibility, highlights the compatibility status of Chinese medical theory.
Be below recipe determination experiment:
Recipe determination and dosage screening experiment, result is as follows:
Experimental result shows Folium Crataegi, Folium Ginkgo, and Folium Ginseng three share has synergistic function experiment
Recipe determination result is that following formulation efficacy is best:
Folium Crataegi 40-50g
Folium Ginkgo 20-30g
Folium Ginseng 30-40g
Compositions of the present invention, the cost of its material medicine and the cost compare table of existing key agents:
Optimum formula in order to above to screen is prepared into pharmaceutical preparation, and carry out pharmacodynamic experiment, result is as follows:
The optimum ratio prescription test of pesticide effectiveness
One, experiment material
1 Experimental Animals Male SD rat (cleaning grade, Shanghai western pul-Bi Kai laboratory animal company limited, the quality certification number: SCXK (Shanghai) 2008-0016), body weight 280-320g.
The pharmaceutical composition that 2 test medicine embodiment of the present invention 1-3 obtain; Positive drug is: verapamil injection (Xuzhou Lai En medicinal liquid company limited, lot number 100301).
3 main agents 2O% urethanes, Evans-blue (the original-pack Cat.No.E2129 of Sigma, Solarbio subpackage Cat.No.E8010), 2, 3, 5-triphenyltetrazolium chloride (TTC) (Sigma company, article No. 127K0716, 10g fills), creatine phosphokinase (CK), CPK-MB (CK-MB), lactic acid dehydrogenase (LDH) test kit (being purchased from Japanese Sysmex company), superoxide dismutase (SOD), myeloperoxidase (MPO) (MPO), malonaldehyde (MDA) test kit (be purchased from Nanjing and build up Bioengineering Research Institute), lidocaine hydrochloride injection (Xuzhou Lai En medicinal liquid company limited, lot number 0811/4), 1% heparin sodium, 10%KCl, 10% neutral formalin.
4 key instrument Power-lab polygraphs (Australia); Automatic clinical chemistry analyzer (Japanese FURUNO ELECTRIC, model: Sysmex chemix-180); Constant water bath box (production of Shanghai Educational Instrument Factory); Desk centrifuge (Anting Scientific Instrument Factory, Shanghai, model: TDL-5); Analytical balance (German Sai Duolisi, model: Sartorius BS124s); KRC-200C toy respirator (Jiangxi Te Li anesthesia equipment company limited).
Two, experimental technique
Rat 40 is got in 1 experiment grouping, rat is divided at random following 5 groups, often organizes 8:
Sham operated rats; Model group; Embodiment 1 medicine, embodiment 2 medicine, embodiment 3 medicine.
The medicinal liquid of 2 administering modes 10min lumbar injection corresponding dosage before left anterior descending branch ligation, model group and sham operated rats give the DMSO solution with same volume by body weight.
3. the copying of rat coronary ligation myocardial ischemia animal model
3.1 preoperative Rat Fast 12h, before the ligation of rat left anterior descending branch, 10min presses medicinal liquid or the DMSO solution of body weight lumbar injection respective volume.
3.2 with 20% urethane 0.6ml/100g intraperitoneal injection of anesthesia rat.Face upward position and fix rat, II leads thought-read electrograph record, and electrocardiogram is abnormal to be eliminated.Cut off downrights, be coated with povidone iodine, row rat trachea otch intubate, connect respirator, respiratory frequency 90 times/min, inspiratory/expiratory 1:1.5, operating pressure is adjusted to No. 1 indicated position and apparent motion thing situation suitably adjusts.
3.3 rat coronary artery left anterior descending branch ligation
After connecting respirator, rat chest is by hair, iodophor disinfection, along left mid-clavicular line longitudinal incision skin, at 2-4 intercostal blunt separation musculus pectoralis superficialis and musculus pectoralis profundus, expose rib, cut off the 3rd, 4,5 or 3,4 root bones (cutting off after with tweezers clamping prevents intercostal vessels hemorrhage again) in the violent place of heartbeat, with eye speculum, thoracic cavity is strutted, expose heart left auricle and whole heart, tear pericardium with tweezers, visible obviously auricle.Under operating lamp, find that there is a shallow white hollow wire navigate between left auricle and pulmonary artery cone along interventricular groove, this is great cardiac vein.Take great cardiac vein as mark, with being installed with No. 5-0 little round needle of No. 5/0 silk thread in left auricle lower edge 2mm place, perpendicular to great cardiac vein inserting needle, at pulmonary artery cone branch pin, thread a needle degree of depth 1.5mm, width 1.5 ~ 2mm.The lidocaine hydrochloride injection of 1 ~ 2 2mg/ml is dripped in heart surface after leaving standstill 3 ~ 5min, one tiny silica gel tube is padded on (self-control of half vacuum blood collection conduit got by silica gel tube) between blood vessel and ligature, by left anterior descending branch, great cardiac vein slip-knot ligation together with silica gel tube.After ligation, 30min unclamps ligature and fills with again, removes respirator and carries out the preparation of next animal model.Sham operated rats is the not ligation at left auricle lower edge position same with between pulmonary conus threading only, and all the other operations are same with operation group.
See that left room antetheca is cyanosis or pale asphyxia, ventricular beat weakens with naked eyes after ligation, in 10min, electrocardiogram is shown in that ST section or T wave height are alarmmed for ligation Success Flag, decline more than 50% with the ST section raised, fill with ishemic part at once again and return to ruddy for Reperfu-sion Success Flag.
4. observation index
4.1ST section changes: II leads thought-read electrograph, observe before ligation, ligation at once, 5min, 10min, 20min, 30min after ligation, Reperfu-sion fills with the change of the ST section, T wave height etc. of rear each time point of 10min, 20min, 30min, 1h, 2h, 3h at once, again, calculates the value (after Δ ST=ligation 30minST value-rear 3h ST value of multiple filling) of Δ ST simultaneously.
4.2 Hemodynamic Changes: 3h after multiple filling, be separated left femoral artery and right carotid, row arterial cannulation, left femoral artery will be inserted containing heparin sodium fluid catheter, conduit other end is connected to pressure transducer, import Power-lab polygraph and trace arterial pressure curve, record systolic arterial pressure (SBP), auterial diastole pressure (DBP); Another conduit containing heparin sodium liquid is inserted in left ventricular cavity from right carotid simultaneously, conduit other end is connected to pressure transducer, import Power-lab polygraph and trace left ventricular pressure (LVP) curve, record left ventricular systolic pressure (LVSP), Left ventricular end diastolic pressure (LVEDP), heart rate (HR), record maximum the climbing speed (+d of left ventricle isovolumic contraction period intraventricular pressure simultaneously
p/ d
tmax), maximum the fall off rate (-d of left ventricle isovolumic relaxation phase intraventricular pressure
p/ d
tmax), t-d
p/ d
t.
4.3Evans-blue/TTC double-staining measure myocardial infarct size: get blood complete after, connect toy respirator, again ligation left anterior descending branch same position, after injecting 1% heparin sodium aqua 1ml from right common carotid artery, (3min has injected the azovan blue PBS solution 6ml of slow injection 37 DEG C 1%, wait for 2min again), then rapid KCl solution execution rat of injecting 1ml 15% from right common carotid artery, makes heart stop at relaxing period.Heart takes off by rapid eye scissors, wipes out rapidly left and right atrium and right ventricle, and with PBS (10mM, the PH=7.4) cleaning of 0 DEG C, wrapped up by heart with food fresh keeping membrane, the refrigerator and cooled being put in-20 DEG C freezes 1 hour.Take out heart is become about 1.5mm by heart dissecting knife to the order crosscut of base portion section according to the apex of the heart, conical flask is put in section, adds in 40ml 1%TTC PBS solution, lucifuge 37 DEG C of water-bath 20min.Immediately 10% formalin is put in section after color is obvious, fixing 24h.Take out, after absorbing a small amount of moisture, numbering, cuts into slices myocardium base surface upward, numbering, and digital camera is taken pictures (all photo cameras are consistent with the distance of section), and order is weighed by number.Myocardial infarction district is canescence, and myocardial ischemia hazardous area is brick-red, and normal myocardium is blue.Trace each district area by Imagetool3.0 image analysis software, and then draw myocardial infarct size, computing formula is:
Myocardial infarct size=weight W1/ ischemic region, infarcted region weight W2
W2=infarcted region weight W1+ ischemia hazardous area weight W3
W1=infarct size 1/ myocardial area 1* 1 weight+infarct size 2/ myocardial area 2*, 2 weight W3=ischemia dangerous area 1/ myocardial area 1*, the 1 weight+ischemia dangerous area 2/ myocardial area 2* that cuts into slices that cuts into slices that cuts into slices cuts into slices 2 weight
Three. data analysis
With SPSS16.0 statistical software, the data obtained is analyzed, the data obtained Mean ± SD represents, ANOVA variance analysis is adopted to compare mean between group, independent sample T inspection is adopted to compare, with P<0.01 or P<0.05 for there being statistical significance model group and sham operated rats, administration group and model group mean.
Four. experimental result
1 Δ ST value: find that electrocardio T ripple is that the back of a bow is raised after heart ligation by the lateral comparison of each time point ST value, ST value is significantly raised and 30min reaches maximum after ligation, deducts the gained Δ ST of 30min, 3h after multiple filling by the ST value of 30min after ligation
1, Δ ST
2(table 1), model group highly significant is greater than blank group (P<0.01), after ligation, 30min deducts the half of Δ ST close to the ST value of 30min after ligation of 3h gained after multiple filling, and pathologic Q ripple appears in 3h after multiple filling, from electrocardiogram, modeling success is described; Each extract group and model group all have significant difference, show that medicine can resist such arrhythmia.
After table 1 ligation, 30min deducts 30min, 3h gained Δ ST value (unit: mV, n=8) after multiple filling
Note: " * * " expression compares P<0.01 with model group.
2 hemodynamic indexs: in each hemodynamic parameter index through surveying left ventricular pressure and femoral artery pressure gained, administration group compares with model group, all has significant difference, shows that compositions has the damaging action that resists myocardial ischemia.
Table 2. left ventricular pressure hemodynamic parameter value (unit: mmHg, n=8)
Note: " * * " represents that model group organizes difference highly significant, P<0.01 with blank; " ◇ " represents that this administration group and model group have significant difference, P<0.05; " ◇ ◇ " represents this administration group and model group difference highly significant, P<0.01.
Table 3. femoral artery hemodynamic parameter value (unit: mmHg, n=8)
| Group | Femoral artery systolic pressure | Femoral artery diastolic pressure | Femoral artery mean pressure |
| Blank group | 124.41±13.27 | 75.18±4.26 | 91.18±2.88 |
| Model group | 123.18±13.57 | 70.56±6.87 | 81.75±7.21＊ |
| Embodiment 1 | 130.91±12.43◇ | 83.62±7.78◇◇ | 95.13±9.27◇ |
| Embodiment 2 | 131.34±7.81◇ | 84.83±12.46◇◇ | 96.82±13.99◇◇ |
| Embodiment 3 | 124.05±17.86 | 77.66±14.39 | 88.17±15.01 |
Note: " * " represents that model group organizes difference highly significant, P<0.01 with blank; " ◇ " represents that this administration group and model group have significant difference, P<0.05; " ◇ ◇ " represents this administration group and model group difference highly significant, P<0.01.
3. myocardial infarct size: result can find out three Chinese People's Anti-Japanese Military and Political College Mus coronary ligation myocardial ischemia reperfusion injury good drug efficacy.
Table 4. respectively organizes myocardial infarct size
Note: " * * " model group and blank group difference highly significant, P<0.01, " ◇ ◇ " represents this administration group and model group difference highly significant, P<0.01.
Five. conclusion
Example composition can Ischemic myocardium reperfusion injury well.
The most preferred Chinese medicine composition of the present invention is a kind of effervescent granule, and have protection ischemia, hypoxic cardiac muscle, alleviate the effect of such damage, drug effect is obvious, has no side effect.In side, each Chinese crude drug is simple and easy to get, cheap, can alleviate patient economy burden, is applicable to promoting the use of.
Detailed description of the invention:
By following specific embodiment, the present invention is further illustrated, but not as restriction.
Embodiment 1, effervescent granule
Get the Folium Crataegi 50g of coarse crushing, Folium Ginkgo 30g, add 8 times of water gaging reflux, extract, 2 times, each 1 hour, merging filtrate, concentrating under reduced pressure to a certain degree, adds ethanol, 60% concentration precipitate with ethanol, ethanol reclaim under reduced pressure, obtain extractum, vacuum drying, obtains Folium Crataegi, Folium Ginkgo extract; Get coarse crushing Folium Ginseng 40g, add 6 times amount 50% reflux, extract, 2 times, each 1 hour, merging filtrate, decompression recycling ethanol, obtains extractum, and suitable quantity of water is dissolved, defat with petroleum ether, and water liquid part is dry, obtains extract of Radix Ginseng leaf;
Take above extract and be about 30g, add citric acid 1g, malic acid 1g, sodium bicarbonate 2g, lactose 35g, sodium lauryl sulphate 3g, sodium citrate 30g, 16 mesh sieves are granulated, and dry, granulate, obtains object 100g.
Embodiment 2, effervescent granule
Get the Folium Crataegi 40g of coarse crushing, Folium Ginkgo 20g, add 10 times of water gaging reflux, extract, 2 times, each 1 hour, merging filtrate, concentrating under reduced pressure to a certain degree, adds ethanol, 65% concentration precipitate with ethanol, ethanol reclaim under reduced pressure, obtain extractum, vacuum drying, obtains Folium Crataegi, Folium Ginkgo extract; Get coarse crushing Folium Ginseng 40g, add 6 times amount 60% reflux, extract, 2 times, each 1 hour, merging filtrate, decompression recycling ethanol, obtains extractum, and suitable quantity of water is dissolved, defat with petroleum ether, and water liquid part is dry, obtains extract of Radix Ginseng leaf; Take above extract 39g, add citric acid 2g, sodium bicarbonate 2g, lactose 30g, sodium lauryl sulphate 4g, sodium citrate 25g, 16 mesh sieves are granulated, and dry, granulate, obtains object.
Embodiment 3, effervescent granule
Get the Folium Crataegi 35g of coarse crushing, Folium Ginkgo 25g, add 8 times of water gaging reflux, extract, 2 times, each 1 hour, merging filtrate, concentrating under reduced pressure to a certain degree, adds ethanol, 60% concentration precipitate with ethanol, ethanol reclaim under reduced pressure, obtain extractum, vacuum drying, obtains Folium Crataegi, Folium Ginkgo extract; Get coarse crushing Folium Ginseng 30g, add 6 times amount 50% reflux, extract, 2 times, each 1 hour, merging filtrate, decompression recycling ethanol, obtains extractum, and suitable quantity of water is dissolved, defat with petroleum ether, and water liquid part is dry, obtains extract of Radix Ginseng leaf; Take above extract 32g, add malic acid 2g, sodium bicarbonate 2g, lactose 35g, sodium lauryl sulphate 3g, sodium citrate 30g, 16 mesh sieves are granulated, and dry, granulate, obtains object.
Claims (10)
1. treat a myocardial ischemia-anoxemia Chinese medicine composition, be prepared from by the raw material of Chinese medicine medicine of following weight ratio
Folium Crataegi 20-50g
Folium Ginkgo 10-30g
Folium Ginseng 10-40g.
2. Chinese medicine composition according to claim 1, is prepared from by the raw material of Chinese medicine medicine of following weight ratio
Folium Crataegi 40-50g
Folium Ginkgo 20-30g
Folium Ginseng 30-40g.
3. Chinese medicine composition according to claim 1 is the pharmaceutical dosage form that any one can be taken.
4. Chinese medicine composition according to claim 1 is peroral dosage form.
5. Chinese medicine composition according to claim 1 is tablet, granule, capsule, oral liquid.
6. Chinese medicine composition according to claim 1 is effervescent granule.
7. the preparation method of Chinese medicine composition according to claim 1, is processed through extraction or other modes by raw material of Chinese medicine, makes pharmaceutically active substance, subsequently, with this material for raw material, when needing, add medicine acceptable carrier, make pharmaceutical preparation according to the routine techniques of galenic pharmacy.
8. preparation method according to claim 7, wherein said active substance can obtain by extracting raw material of Chinese medicine respectively, also can be obtained by the common raw material of Chinese medicine that extracts, also can obtain by other means, as: by pulverizing, squeezing, calcine, grind, sieve, percolation, extraction, water extraction, alcohol extraction, ester carry, the material that method obtains, these active substances can be extractum form such as ketone is carried, chromatography, can be dry extract also can be fluid extract, need to determine to make different concentration according to the difference of preparation.
9. preparation method according to claim 7, preparation method is as follows:
Respectively by medical material coarse crushing, get Folium Crataegi and Folium Ginkgo, add 6-10 times of water gaging reflux, extract, 2 times, each 1 hour, merging filtrate, being evaporated to relative density is 1.05, adds ethanol, 50-65% concentration precipitate with ethanol, ethanol reclaim under reduced pressure, obtain extractum, vacuum drying, obtains Folium Crataegi, Folium Ginkgo extract;
Get Folium Ginseng, add 6-10 times amount 50-70% reflux, extract, 2 times, each 1 hour, merging filtrate, decompression recycling ethanol, obtains extractum, and suitable quantity of water is dissolved, defat with petroleum ether, and water liquid part is dry, obtains extract of Radix Ginseng leaf;
The mixture of above extract is pharmaceutically active substance, with this pharmaceutically active substance for active component, and the mixing of medicine acceptable carrier, according to galenic pharmacy routine techniques, can pharmaceutical composition be prepared into.
10. preparation method according to claim 9, is prepared into effervescent granule, and its preparation method is as follows:
Take extract 100 parts, add citric acid 0-2 part, malic acid 2-0 part, sodium bicarbonate 2 parts, lactose 30-40 part, sodium lauryl sulphate 2-5 part, sodium citrate 25-35 part, with ethanol wet, granulate, dry, granulate, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410592632.1A CN104383033B (en) | 2014-10-29 | 2014-10-29 | A kind of compound gingko leaf preparation treating myocardial ischemia-anoxemia damage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410592632.1A CN104383033B (en) | 2014-10-29 | 2014-10-29 | A kind of compound gingko leaf preparation treating myocardial ischemia-anoxemia damage and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104383033A true CN104383033A (en) | 2015-03-04 |
| CN104383033B CN104383033B (en) | 2016-11-02 |
Family
ID=52601057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410592632.1A Active CN104383033B (en) | 2014-10-29 | 2014-10-29 | A kind of compound gingko leaf preparation treating myocardial ischemia-anoxemia damage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104383033B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771988A (en) * | 2005-11-16 | 2006-05-17 | 张文芳 | Two-leaf composition for treating cardiac and cerebral vascular diseases |
| CN102961517A (en) * | 2012-10-31 | 2013-03-13 | 成都医路康医学技术服务有限公司 | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease |
-
2014
- 2014-10-29 CN CN201410592632.1A patent/CN104383033B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771988A (en) * | 2005-11-16 | 2006-05-17 | 张文芳 | Two-leaf composition for treating cardiac and cerebral vascular diseases |
| CN102961517A (en) * | 2012-10-31 | 2013-03-13 | 成都医路康医学技术服务有限公司 | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease |
Non-Patent Citations (1)
| Title |
|---|
| 李力更等: "三叶保健茶中总黄酮含量的测定研究", 《河北医科大学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104383033B (en) | 2016-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104418744B (en) | A kind of new salvianolic acid compound T, Preparation Method And The Use | |
| CN1762967B (en) | Enoxolone derivative, preparation method and uses | |
| CN101311160A (en) | Method for preparing red sage root salviandic acid A | |
| CN101230003B (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN105232891B (en) | The preparation method of trilliaceae extract and wherein saponins compound and its preparing the application in anti-ischemic heart medicine | |
| CN106344648B (en) | Thymus plant, extract and application thereof | |
| CN101744878B (en) | Water-soluble salvia miltiorrhiza extractive, preparation and application thereof | |
| CN101278939A (en) | Medicament composition for curing cardiovascular and cerebrovascular diseases and method of preparing the same | |
| KR20010049156A (en) | The extract of pine needle and the use thereof | |
| CN101759672B (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
| CN101428050B (en) | Active composition for treating thrombus, cardio-cerebrovascular system diseases | |
| CN104892419B (en) | A kind of total coffee acid ester extract of multiradiate fleabane | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN104383033B (en) | A kind of compound gingko leaf preparation treating myocardial ischemia-anoxemia damage and preparation method thereof | |
| CN104740054B (en) | A kind of pharmaceutical composition for preventing and treating myocardial ischemia and its production and use | |
| CN107982484A (en) | Treat Chinese medicinal compound extract of diabetic retinopathy and its preparation method and application | |
| CN101099775A (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN102293847A (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| CN100509000C (en) | Dispersion tablet of red sage root for coronary artery and preparation method thereof | |
| CN101759751A (en) | Ginsenoside Rg 1 containing ginsenoside Re impurity | |
| CN110664826A (en) | Ophiopogon japonicus saponin D' preparation and new application of hypoglycemic drug thereof | |
| CN103720754A (en) | Drug release system and preparation method of multi-element micro pill used for unclogging arteries | |
| CN101696166B (en) | Preparation method for danshen root salvianolic acid A | |
| CN100502937C (en) | Chinese medicine composition for treating cardiovascular disease and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160617 Address after: 336000 Yuanzhou Jiangxi Pharmaceutical Industrial Park Applicant after: Jiangxi Yaoming Yanghai Pharmaceutical Science and Technology Co., Ltd. Address before: 336000 Yuanzhou pharmaceutical industry park, Jiangxi, Yichun Applicant before: Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Applicant before: Jiangxi Jimin Kexin Group Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170106 Address after: 336000 Yuanzhou Jiangxi Pharmaceutical Industrial Park Patentee after: Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Address before: 336000 Yuanzhou Jiangxi Pharmaceutical Industrial Park Patentee before: Jiangxi Yaoming Yanghai Pharmaceutical Science and Technology Co., Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A compound Ginkgo biloba preparation for the treatment of myocardial ischemia and hypoxia injury and its preparation method Effective date of registration: 20200817 Granted publication date: 20161102 Pledgee: China Merchants Bank Limited by Share Ltd. Nanchang branch Pledgor: JIANGXI JIMINKEXIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2020990000964 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220112 Granted publication date: 20161102 Pledgee: China Merchants Bank Limited by Share Ltd. Nanchang branch Pledgor: JIANGXI JIMINKEXIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2020990000964 |